ChemBriefMerck KGaA Acquires Silence Therapeutics for $1.3 Billion
German drugmaker Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion to enhance its gene silencing capabilities. The all-cash deal values shares at $20 each and is scheduled to close in
reuters · 2026-10-19 05:09